Navigation Links
Governor Gray Davis Joins Genesis Biopharma as Chairman of Corporate Advisory Board

LOS ANGELES, May 23, 2011 /PRNewswire/ -- Genesis Biopharma, Inc. (OTC.BB:GNBP), a biotechnology company developing targeted cancer therapies, today announced that former California Governor, Gray Davis, has joined the company as Chairman of its Corporate Advisory Board. Governor Davis is committed to the improvement of healthcare and advancement of medical technologies.

During his tenure as governor, California became a leader in stem cell research as well as providing the highest levels of funding in the country for cancer and HIV research and treatment. Governor Davis set the most stringent standards for cancer clinical trials and made history by enrolling more children in the federal children's health insurance program (Healthy Families) than any state previously had.  He is currently Of Counsel at the Los Angeles office of law firm Loeb & Loeb.

"I believe personalized medicine is the future – and holds great promise for those suffering from chronic diseases," stated Governor Davis.

Genesis Biopharma Chairman and CEO, Anthony J. Cataldo, added, "Governor Davis brings tremendous value and insight as a person who has implemented his vision for a better healthcare system through advancements in technology and policy. He offers us his experience in organizational leadership, as well as his knowledge in working with regulatory bodies to help  bring our cancer therapies to market to save lives, reduce healthcare costs, and keep America at the forefront of innovative therapeutics."

About Genesis Biopharma, Inc.

Genesis Biopharma, Inc. is a development-stage biotechnology company engaged in the development of targeted cancer therapies. For more information about the company, visit

Forward-Looking Statements

The foregoing press announcement contains forward-looking statements that can be identified by such terminology as "expect," "potential," "suggests," "bodes," "may," "should," "could" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. In particular, management's expectations regarding future research, development and/or commercial results could be affected by, among other things, uncertainties relating to clinical trials and product development; availability of future financing; unexpected regulatory delays or government regulation generally; the company's ability to obtain or maintain patent and other proprietary intellectual property protection; and competition in general. Forward-looking statements speak only as of the date they are made. The company does not undertake to update forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements are made.

SOURCE Genesis Biopharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Maryland Governor Martin OMalley to Visit Novavax in Celebration of HHS-BARDA Contract Award
2. Governor OMalley Announces State Grants Available For Maryland Bio Companies
3. Howard J. Leonhardt Announces Candidacy for Governor of California
4. GreenHouse Energy, Governor Schwarzenegger Join in Driving the Future of Fueling in California
5. Venture Capitalists to Invest in Promising PA Life Science Companies, Governor Rendell Says
6. The Biotechnology Industry Organization Honors Georgia Governor Sonny Perdue as Governor of the Year
7. Governor Rendell Says Life Science Industry Will Fuel New Breakthroughs, Generate Jobs for Decades to Come
8. Jack Davis, Diagnostics Industry Executive, Joins the HistoRx Board of Directors
9. Davis Phinney Foundation Launches Exercise-Focused Tools to Help People Live Well With Parkinsons Disease
10. Tengion Appoints A. Brian Davis Chief Financial Officer
11. Davis Phinney Foundation Launches Every Victory Counts Program to Inform and Empower People to Live Well With Parkinsons
Post Your Comments:
(Date:6/24/2016)... TOKYO , June 24, 2016  Regular discussions on ... to take place between the two entities said Poloz. ... in Ottawa , he pointed to the ... and the federal government. ... Poloz said, "Both institutions have common economic goals, why not ...
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers and ... and the 6000i models are higher end machines that use the more unconventional z-dimension ... light beam from the bottom of the cuvette holder. , FireflySci has developed ...
(Date:6/23/2016)... WA (PRWEB) , ... June 23, 2016 , ... ... announces the release of its second eBook, “Clinical Trials Patient Recruitment and Retention ... recruitment and retention in this eBook by providing practical tips, tools, and strategies ...
(Date:6/23/2016)... , June 23, 2016   Boston ... of novel compounds designed to target cancer stemness ... has been granted Orphan Drug Designation from the ... treatment of gastric cancer, including gastroesophageal junction (GEJ) ... inhibitor designed to inhibit cancer stemness pathways by ...
Breaking Biology Technology:
(Date:6/16/2016)... June 16, 2016 The ... expected to reach USD 1.83 billion by 2024, ... Research, Inc. Technological proliferation and increasing demand in ... expected to drive the market growth. ... The development of advanced multimodal techniques for ...
(Date:6/3/2016)... , June 3, 2016 ... von Nepal hat ... Lieferung hochsicherer geprägter Kennzeichen, einschließlich Personalisierung, Registrierung ... in der Produktion und Implementierung von Identitätsmanagementlösungen. ... Ausschreibung im Januar teilgenommen, aber Decatur wurde ...
(Date:5/24/2016)... Ampronix facilitates superior patient care by providing unparalleled technology to leaders of ... the latest premium product recently added to the range of products distributed by Ampronix. ... ... ... Medical Display- Ampronix News ...
Breaking Biology News(10 mins):